OnKure Therapeutics (OKUR) Set to Announce Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.4067) per share and revenue of $0.17 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.23. On average, analysts expect OnKure Therapeutics to post ($1.47) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

Shares of OKUR opened at $2.63 on Thursday. The company has a market capitalization of $106.25 million, a PE ratio of -0.75 and a beta of 0.12. The company’s 50 day moving average price is $2.96 and its 200 day moving average price is $3.60. OnKure Therapeutics has a 52 week low of $2.01 and a 52 week high of $5.38.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OKUR shares. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Oppenheimer restated an “outperform” rating and set a $14.00 price target on shares of OnKure Therapeutics in a report on Friday, August 14th. Finally, HC Wainwright lowered their price target on shares of OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a report on Monday, July 20th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.50.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.